Healthcare • Biotechnology
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if IMTX is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
25 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: neutral
Last trade: buy 48 days ago
Red flags: 0
83 filers reported a long position in IMTX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | $226.6M | 22.4M | +3.3% |
| RTW INVESTMENTS, LP | $131.1M | 12.9M | +0.6% |
| MONTANOVA CAPITAL, LLC | $113.4M | 11.2M | Unchanged |
| PERCEPTIVE ADVISORS LLC | $105.2M | 10.4M | Unchanged |
| BAKER BROS. ADVISORS LP | $96.3M | 9.5M | -12.9% |
| Jefferies Financial Group Inc. | $65.9M | 6.5M | +28.6% |
| Vestal Point Capital, LP | $62.6M | 6.2M | Unchanged |
| Sofinnova Investments, Inc. | $37.2M | 3.7M | +1.1% |
| MORGAN STANLEY | $22.1M | 2.2M | +1.7% |
| CITADEL ADVISORS LLC | $18.4M | 1.8M | -2% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.